US2015267192A1PendingUtilityA1
Nuclease resistant polynucleotides and uses thereof
Assignee: SHIRE HUMAN GENETIC THERAPIESPriority: Jun 8, 2012Filed: Jun 7, 2013Published: Sep 24, 2015
Est. expiryJun 8, 2032(~5.9 yrs left)· nominal 20-yr term from priority
C07H 21/00C12N 15/111C12N 2320/51C12P 21/02C07H 21/02C12N 2310/3519C07K 14/505
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides, among other things, methods of mRNA stabilizing mRNA and nuclease resistant mRNA prepared in accordance with such methods. In certain embodiments, the nuclease resistant mRNA encodes a functional protein, such as enzyme, and is characterized by its resistance to nuclease digestion, increased half-life and/or its ability to produce increased amounts of the functional protein (e.g., enzyme) encoded thereby.
Claims
exact text as granted — not AI-modified1 . A method of modulating the nuclease resistance of a polynucleotide having a coding region and a non-coding region, the method comprising a step of contacting the polynucleotide with a stabilizing oligonucleotide, thereby modulating the nuclease resistance of the polynucleotide, wherein the stabilizing oligonucleotide is complementary to the non-coding region of the polynucleotide and comprises at least one modified nucleobase.
2 . (canceled)
3 . The method of claim 1 , wherein the RNA is mRNA.
4 . The method of claim 1 , wherein the non-coding region of the polynucleotide is selected from the group of regions consisting of a 3′ untranslated region (UTR), a 5′ untranslated region (UTR), a poly-A tail, a terminal cap, and combination thereof.
5 . The method of claim 1 , wherein the non-coding region of the polynucleotide comprises a poly(A) tail.
6 . The method of claim 5 , wherein the stabilizing oligonucleotide comprises a poly-U sequence.
7 . (canceled)
8 . The method of claim 1 , wherein the stabilizing oligonucleotide is about 1 to about 50 nucleotides in length.
9 - 32 . (canceled)
33 . The method of claim 3 , wherein the mRNA encodes a protein selected from the group consisting of erythropoietin, human growth hormone, cystic fibrosis transmembrane conductance regulator (CFTR), alpha-galactosidase A, alpha-L-iduronidase, iduronate-2-sulfatase, N-acetylglucosamine-1-phosphate transferase, N-acetylglucosaminidase, alpha-glucosaminide acetyltransferase, N-acetylglucosamine 6-sulfatase, N-acetylgalactosamine-4-sulfatase, beta-glucosidase, galactose-6-sulfate sulfatase, beta-galactosidase, beta-glucuronidase, glucocerebrosidase, heparan sulfamidase, hyaluronidase, galactocerebrosidase, ornithine transcarbamylase (OTC), carbamoyl-phosphate synthetase 1 (CPS1), argininosuccinate synthetase (ASS1), argininosuccinate lyase (ASL), and arginase 1 (ARG1).
34 . The method of claim 1 , wherein the stabilizing oligonucleotide and polynucleotide are contacted at a ratio ranging between about 0.01:1 and about 100:1.
35 - 39 . (canceled)
40 . A nuclease resistant mRNA comprising mRNA having a coding region and a non-coding region and a complementary stabilizing oligonucleotide hybridized to at least a portion of the non-coding region of the mRNA, wherein the stabilizing oligonucleotide comprises at least one modified nucleobase, and wherein the nuclease resistant mRNA is more resistant to nuclease degradation relative to the un-hybridized mRNA.
41 - 64 . (canceled)
65 . A method of increasing translation of polypeptide from an mRNA transcript having a coding region and a non-coding region, the method comprising a step of hybridizing a stabilizing oligonucleotide to a portion of the non-coding region of the mRNA transcript thereby increasing amount of the polypeptide translated from the mRNA transcript; and wherein the stabilizing oligonucleotide comprises at least one modified nucleobase.
66 . The method of claim 65 , wherein the non-coding region of the mRNA transcript is selected from the group of regions consisting of a 3′ untranslated region (UTR), a 5′ untranslated region (UTR), a poly-A tail and a terminal cap.
67 - 86 . (canceled)
87 . A method of increasing translation of an exogenous mRNA transcript having a coding region and a non-coding region, the method comprising a step of co-administering the exogenous mRNA transcript with a stabilizing oligonucleotide into a cell; wherein the stabilizing oligonucleotide is complementary to the non-coding region of the mRNA transcript; wherein the co-administering results in increased translation of the exogenous mRNA transcript; and wherein the stabilizing oligonucleotide comprises at least one modified nucleobase.
88 - 119 . (canceled)Join the waitlist — get patent alerts
Track US2015267192A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.